Company / Current Assets
Halozyme Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$825.2M
FY2025
5-year range
$739.0M / $1.1B
FY2021-FY2025
Trend
-24.0%
vs FY2024
Sector context
#67 of 213
Health Care
What the data says
At $825M, Halozyme's current assets ranks #67 of 213 in the Health Care sector. Current Assets has fluctuated over the past 10 years, ranging from $257M in FY2016 to $1.1B in FY2024.
Based on SEC 10-K filings.
$825M in FY2025 with a 5-year CAGR of +8.3%.
Improved from $746M to $825M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +3.7%
- 5-Year CAGR
- +8.3%
- 10-Year CAGR
- -
Sector benchmark
#67 of 213 in Health CareTop 31% of 213This company $825.2M Sector average $2.5B
▼
-67.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +8.3%, indicating consistent growth.
- In FY2025, current assets decreased 24.0% year-over-year.
- Ranks #67 out of 213 companies in the Health Care sector.
- Peak current assets was recorded in FY2024.
Company context
Key Data Points
- Strong profit margin: 47.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 118.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $825.2M | -24.0% |
| FY2024 | $1.1B | +45.4% |
| FY2023 | $746.4M | +1.0% |
| FY2022 | $739.0M | -20.2% |
| FY2021 | $926.3M | +67.0% |
| FY2020 | $554.8M | +2.1% |
| FY2019 | $543.4M | +27.0% |
| FY2018 | $427.8M | -16.2% |
| FY2017 | $510.4M | +99.0% |
| FY2016 | $256.5M | +49.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026